Aclaris Therapeutics ACRS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Key Insights
Critical company metrics and information
Latest Closing Price
$1.83Market Cap
$197.91 MillionPrice-Earnings Ratio
-1.07Total Outstanding Shares
107.92 Million SharesTotal Employees
64Dividend
No dividendIPO Date
October 7, 2015SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
701 lee road, Wayne, PA, 19087Homepage
https://www.aclaristx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-69.77 Million |
| Net Cash Flow From Financing Activities, Continuing | $74.54 Million |
| Net Cash Flow From Investing Activities | $-69.77 Million |
| Net Cash Flow From Operating Activities, Continuing | $-20.07 Million |
| Net Cash Flow | $-15.31 Million |
| Net Cash Flow, Continuing | $-15.31 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss | $-132.06 Million |
| Cost Of Revenue | $2.79 Million |
| Operating Expenses | $157.86 Million |
| Basic Earnings Per Share | $-1.71 |
| Revenues | $18.72 Million |
| Basic Average Shares | $77.30 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $203,000 |
| Comprehensive Income/Loss Attributable To Parent | $-131.86 Million |
| Comprehensive Income/Loss | $-131.86 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $94.38 Million |
| Assets | $220.33 Million |
| Equity | $155.55 Million |
| Equity Attributable To Parent | $155.55 Million |
| Current Assets | $125.95 Million |
| Accounts Payable | $4.69 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ACRS from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.